ClinicalTrials.gg
RecruitingNCT07092280tDCSUpdated Nov 13, 2026

Transcranial Direct Current Stimulation in Children With Autism

An interventional study of Active tDCS and Sham (No Treatment) in Autism Spectrum Disorder and Executive Dysfunction, sponsored by New York State Institute for Basic Research. Recruiting at 1 site in United States. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by New York State Institute for Basic Research · Not applicable, Interventional, and Treatment

How we know

Updated Nov 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Planned enrollment
483rd of 658
24 · median 50
Started
2026
with 46 others
No phase
456 of 773
104 open now
Primary completion
2028-12
later than 163 of 201 live
Registered
716th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 483rd largest by planned enrollment of the 658 interventional ones that give a count, is one of 47 that started in 2026, is one of 456 with no phase, reaches primary completion later than 163 of the 201 other live ones, and was the 716th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

Although many children diagnosed with autism spectrum disorder (ASD) make significant progress in learning and their cognitive skills improve with applied behavior analysis (ABA), there are a significant number of children who show an absence or a plateau in various skills. Deficits in executive functioning are likely to be involved in many of these cognitive and learning disabilities due to poor functioning of the prefrontal cortex. Currently, the use of biological methods for improving learning and cognition is largely unexplored in research and practice.

The aim of this study is to use of transcranial direct current stimulation (tDCS) in combination with ABA to improve the acquisition of educational programs for students with ASD. tDCS is a low-level electrical neurostimulation and is most effective when used in combination with an active training or teaching, facilitating the neuronal circuits used for that task.

tDCS has been used for various indications over a couple of decades and has been shown to be very safe and has been well-tolerated by children with ASD. The mechanism of tDCS is not clear, however animal studies show that tDCS can stimulate the flow of calcium ions through channels in the astrocytes, activating them, and facilitating their role in synapse formation and therefore learning.

Read the detailed description

Children with ASD experience a wide range of outcomes, and not all children respond effectively to behavioral interventions. This study uses a novel biologic intervention that combines electrical brain stimulation with ABA treatment to target some of the cognitive deficits in ASD that until now have been relatively refractory to treatment.

There is accumulating evidence of tDCS being effective in treating the comorbidities as well as the core symptoms of ASD. tDCS is most effective when used simultaneously with an active intervention. In this study, the effects of tDCS alone and in combination with ABA on the executive functioning skills and the core symptoms of ASD will be examined and monitored using an objective neurophysiological test (EEG).

This is a double-blind, sham-controlled crossover study involving 20 participants. tDCS will be administered while ABA therapy is being implemented. Programs aimed at language and other cognitive functions will be emphasized. tDCS will be applied bi-frontally with the anode at F3 and the cathode at F4. Forty stimulation sessions will be done (20 active, 20 sham) lasting 20 minutes per session, at 1 milliampere.

03

Conditions studied

  • Autism Spectrum Disorder
  • Executive Dysfunction

Keywords

  • transcranial direct current stimulation
  • applied behavior analysis
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females between 5 and 12 years with autism
  2. Enrolled in an ABA program (school or in-home) supervised by a Board Certified Behavior Analyst (BCBA)
  3. Stable medical and behavioral treatments for at least 4 weeks prior to, and during the study
  4. Able to tolerate wearing tDCS as determined during a week-long daily desensitization training.

Exclusion criteria

Exclusion Criteria:

  1. Any implanted metal device (heart pacemaker, cochlear implant, surgical clips, etc.)
  2. Severe neurological disorders such as TBI, brain tumor, intracranial infection
  3. Seizure disorder with a seizure within the last two years
  4. Skull defect
  5. Peripheral blindness or deafness
  6. Medication that might affect tDCS: There have been a few studies concerning the effect of various medications on tDCS. Some may block and others may enhance the effects depending on many factors. The assay used to test these medications was its effect on the motor cortex after stimulation and this may not apply to our montages, however, in order to minimize the chances of having medication affect our results, participants taking the following medications will be excluded:

    • Na or Ca channel blockers which will include all anti-seizure medications
    • Medications that affect the NMDA receptors including dextromethorphan, cycloserine
    • Serotonin reuptake inhibitors
    • Dopamine stimulating or blocking medications including pergolide, bromocriptine and all antipsychotic medications
    • Norepinephrine stimulating or blocking agents including propranolol and the stimulants
    • Drugs that can lower seizure threshold [imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, phencyclidine, ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline]
    • Barbiturates, benzodiazepines, meprobamate, chloral hydrate in the past 4 weeks
  7. Acute skin disease
  8. History of magnetic or electrical stimulation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Active tDCS

    Active stimulation first, then crossover to Sham stimulation. Each participant will receive BOTH sham and active tDCS but the order of each will be randomized. The active tDCS and sham are procedurally identical. Participants in both arms will have the initial tingling sensation and the active tDCS stimulation will CONTINUE for 20 minutes at 1 mA (milliamps). All tDCS sessions will occur during ABA therapy.

    Device: Active tDCS

  • Sham comparator
    Sham tDCS

    Sham stimulation first, then crossover to Active stimulation. Each participant will receive BOTH sham and active tDCS but the order of each will be randomized. The active tDCS and sham are procedurally identical. Participants in both arms will have the initial tingling sensation, except in sham stimulation, the current will be DISCONTINUED after 30 seconds while the power indicator remains on for the remainder of 20 minutes at 0 mA (milliamps). All tDCS sessions will occur during ABA therapy.

    Device: Sham (No Treatment)

Interventions

  • DeviceActive tDCS

    Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method used to modulate cortical excitability, which produces facilitatory or inhibitory effects on behaviors. The anodal electrode will be positioned at F3 (using the international 10-20 EEG system) to target the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will undergo 20 active stimulation sessions, each lasting 20 minutes at a continuous 1.0 mA intensity.

  • DeviceSham (No Treatment)

    The anodal electrode will be positioned at F3 (according to the international 10-20 EEG system), targeting the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will receive 20 sessions of sham stimulation, each 20 minutes long. At the start of each session, the current ramps up and remains active for 30 seconds. After 30 seconds, the current is DISCONTINUED (held at 0 mA) but the power indicator stays illuminated for the remainder of the 20-minute session to ensure effective blinding, as is standard in tDCS sham protocols

06

What researchers measure

Primary outcomes

  1. Change in the Behavior Rating Inventory of Executive Function (BRIEF)

    The BRIEF is a parent-reported executive function questionnaire which utilizes T-scores, which has a mean of 50 with a standard deviation of 10, with a range of 10-100

    Time frame: Change measured once per month (at the end of each phase) for 5 months

  2. Change in Electrodncephalogram (EEG)

    Power, sample entropy, Lyapunov exponent, detrended fluctuation analysis, correlation dimension, and recurrence quantitative analysis (RQA) values on all frequency bands (delta, theta, alpha, beta, gamma, and gamma+) will be computed from 2-minute resting EEGs using a portable headset

    Time frame: Change measured once per month (at the end of each phase) for 5 months

Secondary outcomes

  1. Change in the Pervasive Developmental Disorder Behavior Inventory (PDDBI)

    The PDDBI is a parent-reported questionnaire about the symptoms of ASD. The PDDBI utilizes T-scores, which has a mean of 50 with a standard deviation of 10, with a range of 10-100. The higher the Approach/Withdrawal Problems and the higher the Autism scores, the more severe the deficits. The higher the Receptive/Expressive Social Communication scores, the better the competence in these areas

    Time frame: Change measured once per month (at the end of each phase) for 5 months

  2. Change in discrete trial training (DTT) data from applied behavior analysis (ABA) therapy

    Individualized behavior data from ABA therapy. Individualized treatment data may be measured as: response rate per minute/hour/day, percent accuracy, percent interval, and percent correct.

    Time frame: Obtained once at the completion of the study (5 months after the start of the study).

Other outcomes

  1. Vineland Adaptive Behavior Scales (for demographic purposes)

    Parent reported daily living skills. Higher scores indicate better competence. The possible range for these scores is typically from 20 to 160 with a mean of 100 and a standard deviation of 15.

    Time frame: Once during 4-week baseline for the entire study.

  2. Leiter-3 nonverbal intelligence assessment (for demographic purposes)

    Nonverbal intelligence test. Higher scores indicate better competence, with a mean of 100 and a standard deviation of 15. Scores can range from Extremely Low (69 and below) to Very Superior (130+).

    Time frame: Once during 4-week baseline (if a similar test was not done in the past three years) for the entire study.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact jhelen.yoo@opwdd.ny.gov

Supporting information: Study protocol, Informed consent form

Time frame: Start date: January 2026 End date: December 2029

Access criteria: Researchers engaging in independent scientific research will be provided IPD via email.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 25 months is close to that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Nov 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 29, 2025
StartEst.
Nov 25, 2026was Apr 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 1, 2026→Nov 25, 2026
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Apr 1, 2026→Nov 25, 2026
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07092280
Lead sponsor
New York State Institute for Basic Research
Responsible party
Helen Yoo (Research Scientist; Head of Applied Behavior Analysis Laboratory, New York State Institute for Basic Research) — Principal investigator
First posted
Jul 29, 2025
Start date
Nov 25, 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

J. Helen Yoo, Ph.D.
Contact
jhelen.yoo@opwdd.ny.gov
(929) 257-1695
Eric London, M.D.
Contact
naarlondon@gmail.com
(845) 459-5737
J. Helen Yoo, Ph.D.
principal investigator · New York State Institute for Basic Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion